Cover Image
市場調查報告書

糖尿病黃斑部水腫:開發中產品分析

Diabetic Macular Edema - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213121
出版日期 內容資訊 英文 195 Pages
訂單完成後即時交付
價格
Back to Top
糖尿病黃斑部水腫:開發中產品分析 Diabetic Macular Edema - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 195 Pages
簡介

糖尿病黃斑部水腫(DME),是糖尿病患者的視網膜血管受傷害,血液中的水分和脂肪漏出,在視物中心部位的黃斑部產生浮腫的狀態(黃斑部水腫)。有視野不良、飛蚊症、複視的症狀,未治療的話會導致失明。原因是年齡和糖尿病。

本報告提供糖尿病黃斑部水腫治療藥的開發情形調查分析、開發中產品的概要、臨床實驗的各階段的產品概要,再加上主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等相關有系統的資訊。

目錄

簡介

糖尿病黃斑部水腫概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

治療藥的開發作的企業

  • F. Hoffmann-La Roche Ltd.
  • Allergan, Inc.
  • pSivida Corp.
  • GlaxoSmithKline plc
  • Quark Pharmaceuticals, Inc.
  • 參天製藥
  • Astellas Pharma Inc.
  • 興和
  • Pfizer Inc.
  • Genmab A/S
  • TheraKine Ltd.
  • iCo Therapeutics Inc.
  • NicOx S.A.
  • Regeneron Pharmaceuticals, Inc.
  • Handok Inc.
  • ThromboGenics NV
  • Foamix Ltd.
  • Acucela Inc.
  • 千壽製藥
  • Molecular Design International, Inc.
  • Pfenex Inc.
  • Icon Bioscience, Inc.
  • Eleven Biotherapeutics
  • Ampio Pharmaceuticals, Inc.
  • ActiveSite Pharmaceuticals, Inc.
  • AlphaMab Co., Ltd

治療藥的評估

  • 單獨療法的情況
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • dexamethasone acetate
  • aflibercept
  • fluocinolone acetonide
  • aflibercept
  • DMI-5207
  • betamethasone
  • darapladib
  • iCo-007
  • ocriplasmin
  • ripasudil
  • PF-655
  • MP-0112
  • AKB-9778
  • difluprednate
  • PF-04634817
  • 49-B
  • dexamethasone dipropionate
  • KH-902
  • ALG-1001
  • fluticasone propionate
  • ranibizumab
  • emixustat hydrochloride
  • teprotumumab
  • nesvacumab
  • Drug For Diabetic Macular Edema
  • NCX-434
  • ASP-440
  • NCX-422
  • AVA-101
  • ranibizumab biosimilar
  • Plasma Kallikrein Inhibitors Programme
  • EBI-018
  • Small Molecule to Inhibit VAP-1 for Diabetic Macular Edema
  • EBI-029
  • Plasma Kallikrein Inhibitors Programme
  • OPK-20018
  • ranibizumab biosimilar
  • Protein Therapeutic For Diabetic Macular Edema
  • Peptide For Diabetic Macular Edema
  • HL-5511
  • minocycline Gel

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8286IDB

Summary

Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H2 2016', provides an overview of the Diabetic Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
  • The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects
  • The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Macular Edema Overview
  • Therapeutics Development
    • Pipeline Products for Diabetic Macular Edema - Overview
    • Pipeline Products for Diabetic Macular Edema - Comparative Analysis
  • Diabetic Macular Edema - Therapeutics under Development by Companies
  • Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes
  • Diabetic Macular Edema - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Diabetic Macular Edema - Products under Development by Companies
  • Diabetic Macular Edema - Products under Investigation by Universities/Institutes
  • Diabetic Macular Edema - Companies Involved in Therapeutics Development
    • Aciont Inc.
    • ActiveSite Pharmaceuticals, Inc.
    • Adverum Biotechnologies, Inc.
    • Aerpio Therapeutics, Inc.
    • Allergan Plc
    • Ampio Pharmaceuticals, Inc.
    • Araim Pharmaceuticals, Inc.
    • Astellas Pharma Inc.
    • Boehringer Ingelheim GmbH
    • Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
    • Clonz Biotech Private Limited
    • 7 Coherus BioSciences, Inc.
    • EyeGate Pharmaceuticals, Inc.
    • EyeGene, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Formycon AG
    • Genmab A/S
    • Icon Bioscience, Inc.
    • Kala Pharmaceuticals, Inc.
    • Kalvista Pharmaceuticals Ltd
    • Kowa Company, Ltd.
    • Mabion SA
    • NicOx S.A.
    • Oculis ehf
    • Ohr Pharmaceutical Inc.
    • Pfizer Inc.
    • Precision Ocular Ltd
    • pSivida Corp.
    • Regeneron Pharmaceuticals, Inc.
    • Santen Pharmaceutical Co., Ltd.
    • SciFluor Life Sciences, LLC
    • Senju Pharmaceutical Co., Ltd.
    • Stealth BioTherapeutics Inc.
    • Sucampo Pharmaceuticals, Inc.
    • ThromboGenics NV
    • Verseon Corporation
    • Xbrane Biopharma AB
  • Diabetic Macular Edema - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (aflibercept + nesvacumab) - Drug Profile
    • abicipar pegol - Drug Profile
    • ACX-107 - Drug Profile
    • aflibercept biosimilar - Drug Profile
    • AKB-9778 - Drug Profile
    • ALG-1001 - Drug Profile
    • Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile
    • ASP-440 - Drug Profile
    • ASP-8232 - Drug Profile
    • ASPPDC-010 - Drug Profile
    • AVA-101 - Drug Profile
    • BI-1026706 - Drug Profile
    • Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile
    • cibinetide - Drug Profile
    • conbercept - Drug Profile
    • danazol - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexamethasone dipropionate - Drug Profile
    • dexamethasone dipropionate XR - Drug Profile
    • difluprednate - Drug Profile
    • Drug for Diabetic Macular Edema - Drug Profile
    • Drugs for Retinal Diseases - Drug Profile
    • EBI-031 - Drug Profile
    • EG-Mirotin - Drug Profile
    • elamipretide - Drug Profile
    • fluocinolone acetonide SR - Drug Profile
    • JDE-006 - Drug Profile
    • KVD-001 - Drug Profile
    • loteprednol etabonate - Drug Profile
    • NCX-422 - Drug Profile
    • NCX-434 - Drug Profile
    • NM-108 - Drug Profile
    • OLX-303 - Drug Profile
    • PF-655 - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • RC-1 Alpha - Drug Profile
    • ripasudil - Drug Profile
    • RTU-1096 - Drug Profile
    • SF-0166 - Drug Profile
    • Small Molecule for Diabetic Macular Edema - Drug Profile
    • Small Molecule to Inhibit Kallikrein for Diabetic Macular Edema - Drug Profile
    • Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema - Drug Profile
    • Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile
    • squalamine lactate - Drug Profile
    • teprotumumab - Drug Profile
    • TG-931 - Drug Profile
    • THR-149 - Drug Profile
    • triamcinolone acetonide - Drug Profile
    • VA-999272 - Drug Profile
  • Diabetic Macular Edema - Dormant Projects
  • Diabetic Macular Edema - Discontinued Products
  • Diabetic Macular Edema - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Macular Edema, H2 2016
  • Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Diabetic Macular Edema - Pipeline by Aciont Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by Adverum Biotechnologies, Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2016
  • Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co., Ltd., H2 2016
  • Diabetic Macular Edema - Pipeline by Clonz Biotech Private Limited, H2 2016
  • Diabetic Macular Edema - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by EyeGene, Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Diabetic Macular Edema - Pipeline by Formycon AG, H2 2016
  • Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2016
  • Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Ltd, H2 2016
  • Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H2 2016
  • Diabetic Macular Edema - Pipeline by Mabion SA, H2 2016
  • Diabetic Macular Edema - Pipeline by NicOx S.A., H2 2016
  • Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2016
  • Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by Pfizer Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by Precision Ocular Ltd, H2 2016
  • Diabetic Macular Edema - Pipeline by pSivida Corp., H2 2016
  • Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
  • Diabetic Macular Edema - Pipeline by SciFluor Life Sciences, LLC, H2 2016
  • Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016
  • Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2016
  • Diabetic Macular Edema - Pipeline by Verseon Corporation, H2 2016
  • Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Diabetic Macular Edema - Dormant Projects, H2 2016
  • Diabetic Macular Edema - Dormant Projects (Contd..1), H2 2016
  • Diabetic Macular Edema - Dormant Projects (Contd..2), H2 2016
  • Diabetic Macular Edema - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Diabetic Macular Edema, H2 2016
  • Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top